News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ZS Pharma (ZSPH) Announces Allowance Of Two U.S. Patent Applications For ZS-9


7/8/2014 6:25:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

COPPELL, Texas, July 8, 2014 (GLOBE NEWSWIRE) -- ZS Pharma, a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, announced today that it has received Notices of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. Patent Application Numbers 13/371,080 and 14/036,489 for ZS-9 (sodium zirconium cyclosilicate), the Company's product candidate in Phase 3 development for the treatment of hyperkalemia. The 13/371,080 Application describes compositions of matter that include ZS-9 and the 14/036,489 Application covers methods of treating hyperkalemia with compositions described in 13/371,080. The patents to be issued from these applications carry a patent term to at least 2032.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
ZS Pharma
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES